留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

安罗替尼在肝癌中耐药的差异mRNA筛选

谷俊谋 王立博 曾德俊 陆勤伟 董凯 梁若鹏 王维杰 朱荣涛 孙玉岭

谷俊谋, 王立博, 曾德俊, 等. 安罗替尼在肝癌中耐药的差异mRNA筛选[J]. 临床肝胆病杂志, 2021, 37(2): 358-363. DOI: 10.3969/j.issn.1001-5256.2021.02.022
引用本文: 谷俊谋, 王立博, 曾德俊, 等. 安罗替尼在肝癌中耐药的差异mRNA筛选[J]. 临床肝胆病杂志, 2021, 37(2): 358-363. DOI: 10.3969/j.issn.1001-5256.2021.02.022
GU JM, WANG LB, ZENG DJ, et al. Differentially expressed mRNA involved in the resistance of liver cancer to anlotinib[J]. J Clin Hepatol, 2021, 37(2): 358-363. DOI: 10.3969/j.issn.1001-5256.2021.02.022
Citation: GU JM, WANG LB, ZENG DJ, et al. Differentially expressed mRNA involved in the resistance of liver cancer to anlotinib[J]. J Clin Hepatol, 2021, 37(2): 358-363. DOI: 10.3969/j.issn.1001-5256.2021.02.022

安罗替尼在肝癌中耐药的差异mRNA筛选

DOI: 10.3969/j.issn.1001-5256.2021.02.022
基金项目: 

国家自然科学基金 81870457

国家自然科学基金 81900558

详细信息
    作者简介:

    谷俊谋(1993—),男,主要从事肝脏相关疾病的研究

    通讯作者:

    孙玉岭,doctorssh@126.com

  • 利益冲突声明:本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突,特此声明。
  • 作者贡献声明:谷俊谋负责课题设计,资料分析,撰写论文;王立博、曾德俊、陆勤伟、董凯、梁若鹏、王维杰、朱荣涛参与收集数据,修改论文;孙玉岭负责拟定写作思路,指导撰写文章并最后定稿。
  • 中图分类号: R735.7

Differentially expressed mRNA involved in the resistance of liver cancer to anlotinib

  • 摘要:   目的  运用ceRNA芯片筛选可能参与肝癌细胞对安罗替尼耐药过程的mRNA。  方法  利用大剂量冲击联合低剂量诱导的方法建立对安罗替尼耐药的肝癌细胞,用CCK8实验进行验证耐药细胞在安罗替尼作用下的细胞增殖差异;运用ceRNA芯片检测耐药肝癌细胞与正常肝癌细胞的基因表达差异;运用实时荧光定量PCR(real-time PCR)对部分芯片测出的部分基因差异进行验证。计量资料两组间比较采用独立样本t检验,Kaplan-Meier法对肝癌样本的总生存期进行生存分析,log-rank检验比较生存率差异。芯片筛选结果使用Fisher精确检验。  结果  耐药肝癌细胞与正常肝癌细胞基因表达差异较大,通过缩减范围筛选出差异最大的10个基因进行分析。与耐药和肿瘤生长相关的基因有4个,分别为BIRC2、BIRC7、ABCC2、MAPK8。其中BIRC2、ABCC2、MAPK8表达水平下降(P值分别为0.001 4、0.001 2、0.011 8),BIRC7的表达水平增多(P<0.001)。real-time PCR的验证结论与芯片一致(t值分别为10.74、32.65、18.34、2.80,P值分别为0.000 4、0.000 1、0.000 1、0.044 8)。BIRC7的高表达与MAPK8的低表达对应显著减少的生存期(P值分别0.022 0、0.005 6)。  结论  BIRC2、BIRC7、ABCC2、MAPK8在对安罗替尼耐药的肝癌细胞中差异表达,可能参与了肝癌细胞对安罗替尼耐药的过程。
  • 图  1  CCK8法检测安罗替尼对Huh7和Huh7/R的抑制作用

    图  2  差异mRNA热图见二维码

    图  3  正常肝癌细胞与耐药肝癌细胞差异基因的GO富集分析图

    图  4  正常肝癌细胞与耐药肝癌细胞差异基因的KEGG pathway分析图

    图  5  4个基因的mRNA在正常肝癌细胞和耐药肝癌细胞中的表达水平比较

    注:a, BIRC2;b, ABCC2;c, MAPK8;d.BIRC7。

    图  6  BIRC2、ABCC2、MAPK8、BIRC7的生存分析

    注:a, BIRC2; b,ABCC2; c, MAPK8;d, BIRC7。

  • [1] Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.007

    中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007
    [2] WANG S, WU QW, LI XK, et al. Interpretation of guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(5): 996-999. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.05.009

    王姗, 吴庆旺, 李小科, 等. 《原发性肝癌诊疗规范(2019年版)》解读[J].临床肝胆病杂志, 2020, 36(5): 996-999. DOI: 10.3969/j.issn.1001-5256.2020.05.009
    [3] SUN B, YANG XZ, XIE F, et al. Effect of sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation on the survival of patients with hepatocellular carcinoma[J]. J Clin Hepatol, 2019, 35(1): 104-108. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.01.019

    孙斌, 杨晓珍, 谢放, 等.索拉非尼联合经肝动脉化疗栓塞术和射频消融对肝细胞癌患者生存期的影响[J].临床肝胆病杂志, 2019, 35(1): 104-108. DOI: 10.3969/j.issn.1001-5256.2019.01.019
    [4] HE Z, YU Y, NONG Y, et al. Hepatitis B virus X protein promotes hepatocellular carcinoma invasion and metastasis via upregulating thioredoxin interacting protein[J]. Oncol Lett, 2017, 14(2): 1323-1332. DOI: 10.3892/ol.2017.6296
    [5] LIN B, SONG X, YANG D, et al. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1[J]. Gene, 2018, 654: 77-86. DOI: 10.1016/j.gene.2018.02.026
    [6] YE SL. Downstaging and conversion treatment of intermediate and advanced liver cancer should be taken seri-ously[J]. J Clin Hepatol, 2020, 36(2): 249-251. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.001

    叶胜龙.重视中晚期肝癌的降期转化治疗[J].临床肝胆病杂志, 2020, 36(2): 249 -251. DOI: 10.3969/j.issn.1001-5256.2020.02.001
    [7] WANG YM, MENG Y, SHI XN, et al. Analysis of clinical efficacy, safety and prognosis of anlotinib hydrochloride in the treatment of advanced primary liver cancer[J]. Chin J Hepatol, 2020, 28(7): 619-624. (in Chinese) DOI: 10.3760/cma.j.cn501113-20191020-00385

    王亚梦, 孟宇, 师霄楠, 等.盐酸安罗替尼治疗晚期原发性肝癌的临床疗效、安全性及预后分析[J].中华肝脏病杂志, 2020, 28(7): 619-624. DOI: 10.3760/cma.j.cn501113-20191020-00385
    [8] PAN YF, FENG XL, YU X, et al. The clinical efficacy of transarterial chemoembolization combined with anlotinib in the treatment of advanced hepatocellular carcinoma[J]. Chin J Exp Surg, 2020, 37(3): 531-533. (in Chinese) DOI: 10.3760/cma.j.issn.1001-9030.2020.03.040

    潘延凤, 冯晓丽, 余雪, 等.肝动脉化疗栓塞联合安罗替尼治疗晚期肝癌的临床研究[J].中华实验外科杂志, 2020, 37(3): 531-533. DOI: 10.3760/cma.j.issn.1001-9030.2020.03.040
    [9] YANG B, XIE H, WANG CP, et al. Study on Inhibition of arotinib on human intrahepatic cholangiocarcinoma cell line HCC-9810[J]. Chin J Med Guide, 2017, 19(12): 1389-1391. (in Chinese) DOI: 10.3969/j.issn.1009-0959.2017.12.037

    杨斌, 谢辉, 王春平, 等.安罗替尼对人肝内胆管细胞癌细胞系HCC-9810作用研究[J].中国医药导刊, 2017, 19(12): 1389-1391. DOI: 10.3969/j.issn.1009-0959.2017.12.037
    [10] LIU K, YU Q, LI H, et al. BIRC7 promotes epithelial-mesenchymal transition and metastasis in papillary thyroid carcinoma through restraining autophagy[J]. Am J Cancer Res, 2020, 10(1): 78-94.
    [11] DOU H, BUETOW L, SIBBET GJ, et al. BIRC7-E2 ubiquitin conjugate structure reveals the mechanism of ubiquitin transfer by a RING dimer[J]. Nat Struct Mol Biol, 2012, 19(9): 876-883. DOI: 10.1038/nsmb.2379
    [12] SAMANTA D, HUANG TY, SHAH R, et al. BIRC2 expression impairs anti-cancer immunity and immunotherapy efficacy[J]. Cell Rep, 2020, 32(8): 108073. DOI: 10.1016/j.celrep.2020.108073
    [13] GYRD-HANSEN M, MEIER P. IAPs: From caspase inhibitors to modulators of NF-kappaB, inflammation and cancer[J]. Nat Rev Cancer, 2010, 10(8): 561-574. DOI: 10.1038/nrc2889
    [14] MA O, CAI WW, ZENDER L, et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression[J]. Cancer Res, 2009, 69(6): 2559-2567. DOI: 10.1158/0008-5472.CAN-08-2929
    [15] CAMPBELL GR, BRUCKMAN RS, CHU YL, et al. SMAC mimetics induce autophagy-dependent apoptosis of HIV-1-infected resting memory CD4+ T cells[J]. Cell Host Microbe, 2018, 24(5): 689-702. DOI: 10.1016/j.chom.2018.09.007
    [16] CORPECHOT C, BARBU V, CHAZOUILLÈRES O, et al. Genetic contribution of ABCC2 to Dubin-Johnson syndrome and inherited cholestatic disorders[J]. Liver Int, 2020, 40(1): 163-174. DOI: 10.1111/liv.14260
    [17] RAZALI RH, NOORIZHAB M, JAMARI H, et al. Association of ABCC2 with levels and toxicity of methotrexate in malaysian childhood acute lymphoblastic leukemia (ALL)[J]. Pediatr Hematol Oncol, 2020, 37(3): 185-197. DOI: 10.1080/08880018.2019.1705949
    [18] WU L, LI Y, SONG Y, et al. A recurrent ABCC2 p.G693R mutation resulting in loss of function of MRP2 and hyperbilirubinemia in Dubin-Johnson syndrome in China[J]. Orphanet J Rare Dis, 2020, 15(1): 74. DOI: 10.1186/s13023-020-1346-4
    [19] NGAN HL, LIU Y, FONG AY, et al. MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling[J]. Life Sci Alliance, 2020, 3(6): e201900545. DOI: 10.26508/lsa.201900545
    [20] XU P, ZHANG G, HOU S, et al. MAPK8 mediates resistance to temozolomide and apoptosis of glioblastoma cells through MAPK signaling pathway[J]. Biomed Pharmacother, 2018, 106: 1419-1427. DOI: 10.1016/j.biopha.2018.06.084
  • 加载中
图(6)
计量
  • 文章访问数:  13
  • HTML全文浏览量:  2
  • PDF下载量:  6
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-09-29
  • 修回日期:  2020-11-27
  • 刊出日期:  2021-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回